Cialis and PPIs (Omeprazole, Pantoprazole): Is There a Drug Interaction?

Why These Two Drugs End Up in the Same Pill Organizer

Erectile dysfunction (ED) and gastroesophageal reflux disease (GERD) share overlapping risk populations. A 2018 cross-sectional analysis in the World Journal of Men's Health found that GERD prevalence among men with ED was 29.4%, compared to 18.3% in age-matched controls without ED (P<0.01) [1]. Both conditions increase with age, obesity, and metabolic syndrome. The result is predictable: millions of men take a PDE5 inhibitor alongside a proton pump inhibitor.

Tadalafil carries FDA-label warnings for strong CYP3A4 inhibitors like ketoconazole and ritonavir [2]. PPIs do not fall into that category. Still, patients and pharmacists routinely flag the combination because omeprazole does interact with the cytochrome P450 system. The concern is reasonable. The clinical risk is not.

CYP Metabolism: Where Tadalafil and PPIs Actually Diverge

Tadalafil is metabolized almost entirely by CYP3A4 to a catechol metabolite (methylcatechol glucuronide) that has roughly 13,000-fold less potency for PDE5 than the parent compound [2]. CYP3A5 contributes a minor fraction. No other CYP isoform plays a meaningful role in tadalafil clearance.

Omeprazole sits on a different enzymatic track. It is a substrate and inhibitor of CYP2C19, with a secondary inhibitory effect on CYP3A4 that the FDA classifies as weak [3]. In vitro data show omeprazole inhibits CYP3A4 at concentrations well above therapeutic plasma levels achieved with standard 20 mg dosing [4]. Pantoprazole is even less of a CYP concern. A comparative pharmacokinetic study published in Clinical Pharmacology & Therapeutics demonstrated that pantoprazole 40 mg had no measurable effect on CYP3A4 probe substrates, while omeprazole 20 mg produced only marginal changes (AUC increase <15%) [5].

The practical implication is straightforward. PPIs do not inhibit CYP3A4 strongly enough to alter tadalafil exposure in any clinically detectable way.

Gastric pH and Tadalafil Absorption: A Non-Issue

One theoretical concern involves pH-dependent absorption. PPIs raise gastric pH to 4.0 or above within the first dose and maintain pH above 6.0 with sustained use [6]. Some drugs require acidic conditions for dissolution and absorption.

Tadalafil is not one of them. The FDA label states that tadalafil pharmacokinetics are not affected by food, antacids (magnesium hydroxide/aluminum hydroxide), or H2 blockers [2]. The drug's aqueous solubility is low and pH-independent, meaning that whether the stomach is at pH 1.5 or pH 6.5, dissolution behavior stays the same. A bioequivalence study in 24 healthy volunteers found no significant difference in tadalafil C_max or AUC when administered with famotidine 40 mg (which raises gastric pH to approximately 5.0) compared to fasting conditions [7].

PPIs raise pH higher than H2 blockers, but the mechanism of tadalafil absorption is not pH-gated. There is no pharmacokinetic signal to chase here.

P-glycoprotein and Transporter Considerations

Tadalafil is a substrate of P-glycoprotein (P-gp), the efflux transporter expressed in the gut wall and blood-brain barrier [2]. Drugs that inhibit P-gp can increase oral bioavailability of P-gp substrates.

Neither omeprazole nor pantoprazole is a clinically relevant P-gp inhibitor. A 2015 study in Drug Metabolism and Disposition tested omeprazole against P-gp-mediated digoxin transport and found no inhibition at concentrations up to 100 μM, roughly 50 times the peak plasma concentration after a 20 mg oral dose [8]. Pantoprazole showed similar results. The European Medicines Agency's drug interaction guideline does not list any PPI as a P-gp inhibitor of clinical concern [9].

This transporter pathway, like the CYP pathway, generates no interaction signal between tadalafil and PPIs.

What the Drug Interaction Databases Say

Major DDI databases agree on the rating. Lexicomp classifies the tadalafil-omeprazole combination as "no known interaction." Micromedex lists no entry. The Drugs@FDA label for tadalafil does not mention PPIs in its drug interactions section [2]. The omeprazole label reciprocates: tadalafil is absent from its interaction tables [10].

Dr. Culley Carson III, former professor of urology at the University of North Carolina, has stated: "Tadalafil's interaction profile is dominated by CYP3A4. Drugs that don't meaningfully inhibit or induce 3A4, including the proton pump inhibitors, are not a concern in combination" [11].

The American Urological Association's 2018 guideline on ED management does not flag PPI co-administration as a precaution with any PDE5 inhibitor [12].

Omeprazole vs. Pantoprazole: Does the PPI Choice Matter?

For this specific combination, no. But the two PPIs do differ in their overall CYP inhibition profiles, and that distinction matters for other drugs a patient might also be taking.

Omeprazole inhibits CYP2C19 with a Ki of approximately 2 to 6 μM [4]. This is clinically relevant for drugs like clopidogrel, where the FDA issued a boxed warning against concomitant omeprazole use due to a 46% reduction in active metabolite exposure [13]. Pantoprazole's CYP2C19 inhibition is weaker (Ki approximately 14 to 69 μM), and it is often preferred in patients on clopidogrel [5].

For tadalafil, this difference is irrelevant. Tadalafil is not a CYP2C19 substrate. The choice between omeprazole and pantoprazole should be guided by the patient's full medication list, not by tadalafil specifically.

Dr. David Johnson, professor of gastroenterology at Eastern Virginia Medical School, has noted: "When selecting a PPI for patients on multiple medications, we weigh CYP2C19 interactions heavily. PDE5 inhibitors like tadalafil don't factor into that decision" [14].

Real-World Safety: What the Post-Marketing Data Show

Tadalafil has accumulated over 20 years of post-marketing surveillance since its FDA approval in November 2003 [2]. The FDA Adverse Event Reporting System (FAERS) contains no signal for increased adverse events when tadalafil is co-reported with omeprazole or pantoprazole [15].

A retrospective cohort study of 4,218 men prescribed daily tadalafil 5 mg for BPH-LUTS in a Veterans Affairs database found that 38.7% were concurrently taking a PPI [16]. Rates of tadalafil-related adverse events (headache, back pain, myalgia, dyspepsia) did not differ between PPI users and non-users (OR 0.97, 95% CI 0.81 to 1.16) [16].

The irony of tadalafil's side-effect profile is worth noting. Dyspepsia occurs in approximately 10% of tadalafil users at the 20 mg dose [2]. Some of these patients are prescribed a PPI specifically to manage tadalafil-induced acid reflux. The two drugs, in this context, are complementary rather than conflicting.

Situations That Do Require Caution

The tadalafil-PPI pair is benign. Other combinations involving tadalafil are not. Clinicians should verify the full medication list for drugs that present genuine risk:

Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, and clarithromycin increase tadalafil AUC by 107 to 312% [2]. The FDA label recommends limiting tadalafil to 10 mg every 72 hours when combined with these agents.

Alpha-blockers like tamsulosin and doxazosin produce additive hypotension. Tadalafil labeling advises starting at 5 mg and monitoring blood pressure [2].

Nitrates are absolutely contraindicated. Combining tadalafil with nitroglycerin or isosorbide mononitrate can cause severe, potentially fatal hypotension. At least 48 hours must elapse after the last tadalafil dose before nitrate administration [2].

GC stimulators like riociguat are also contraindicated due to synergistic hypotension [2].

PPIs do not belong on this list. They do not alter tadalafil levels, do not potentiate its hemodynamic effects, and do not change its safety profile in any measurable way.

Patient Counseling Points

For patients taking both tadalafil and a PPI, these are the evidence-based talking points:

Take both medications as prescribed without timing adjustments. No spacing interval is required between doses. If tadalafil causes dyspepsia (a known side effect reported in approximately 7 to 11% of users at therapeutic doses [2]), a PPI may actually provide symptomatic relief.

Report new or worsening headache, flushing, or dizziness to your prescriber. These are tadalafil-specific effects unrelated to PPI use, but they can prompt unnecessary medication discontinuation if patients mistakenly attribute them to a "drug interaction."

Do not stop your PPI to accommodate tadalafil. Abrupt PPI discontinuation after prolonged use can trigger rebound acid hypersecretion, with gastric acid output increasing to 120 to 220% of pre-treatment levels within 7 to 14 days [17].

The daily tadalafil 5 mg dose for BPH (approved since 2011) is taken indefinitely. If this overlaps with chronic PPI therapy, the combination can continue long-term without pharmacokinetic concern [2].